Hillemanns P, Zikan M, Forget F, Denys HG, Baurain JF, Rob L, Woelber L, Blecharz P, Bidzinski M, Chovanec J, Marmé F, Link T, Dannecker C, Rosholm A, Berg KCG, Oliveri RS, Lindemann K, VB C-02 investigators, VB C-02 study (2025)
Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study
J Immunother Cancer, 13 (1)
DOI 10.1136/jitc-2024-010827, PubMed 39773564

Bischof K, Holth A, Bassarova A, Davidson B (2024)
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
Pathol Res Pract, 266, 155787 (in press)
DOI 10.1016/j.prp.2024.155787, PubMed 39709875

Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J (2024)
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Gynecol Oncol, 192, 128-136 (in press)
DOI 10.1016/j.ygyno.2024.12.003, PubMed 39657575